Cognitive factors in schizophrenia: Causes, impact, and treatment

CNS Spectrums

Volumn 9, Issue 10 SUPPL. 11, 2004, Pages 15-24

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2 ANTAGONIST; SERTINDOLE; TRIFLUOPERAZINE; ZIPRASIDONE;

ALERTNESS; ATTENTION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISEASE SEVERITY; EMPLOYMENT; HUMAN; INDEPENDENCE; LEARNING; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL INTERACTION; SPATIAL MEMORY; SYMPTOM; VERBAL MEMORY;

EID: 8144221759     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900025098     Document Type: Conference Paper

References (76)

1. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003;1003:138-158.
2. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004;174:32-38.
3. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel anitpsychotic treatment. Am J Psychiatry. 2001;158:176-184.
4. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233-255.
5. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of dozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res. 1999;37:1-11.
6. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101-113.
7. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiatry. 1999;56:781-787.
8. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am. 2003;26:25-40.
9. Schuepbach D, Keshavan MS, Kmiec JA, Sweeney JA. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophr Res. 2002;53:249-261.
10. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 1990;16:477-499.
11. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367-380.
12. Purdon SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci. 2000;25:108-116.
13. Crow TJ. Positive and negative schizophrenia and their response to dopamine. Br J Psychiatry. 1980;137:383-386.
14. Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull. 1985;11:471-486.
15. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924-926.
16. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51:124-131.
17. Heaton RK, Crowley TJ. Effect of psychiatric disorders and their somatic treatments on neuropsychological test results. In: Filskov S, Boltl TJ, eds. Handbook of Clinical Neuropsychology. New York, NY: John Wiley & Sons; 1981:481-525.
18. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330.
19. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239-246.
20. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155:1196-1201.
21. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:473-479.
22. Lysaker P, Bell M, Beam-Goulet J. Wisconsin card sorting test and work performance in schizophrenia. Psychiatry Res. 1995;56:45-51.
23. Meltzer HY, Thompson PA, Lee MA, Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 1996;14(Suppl 3):27S-33S.
24. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25:21-31.
25. Heaton RK, Chelune GJ, Lehman RA. Using neuropsychological and personality tests to assess the likelihood of patient employment. J Nerv Ment Dis. 1978;166:408-416.
26. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res. 2000;45:175-184.
27. Penn DL, Mueser KT, Spaulding W, Hope DA, Reed D. Information processing and social competence in chronic schizophrenia. Schizophr Bull. 1995;21:269-281.
28. Liberman RP, Corrigan PW. Designing new psychosodal treatments for schizophrenia. Psychiatry. 1993;56:238-249; discussion 250-233.
29. Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Ann N Y Acad Sci. 1988;537:330-338.
30. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci U S A. 1999;96:13432-13437.
31. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205:929-932.
32. Watanabe M, Kodama T, Hikosaka K. Increase of extracellular dopamine in primate prefrontal cortexs during a working memory task. J Neurophysiol. 1997;78:2795-2798.
33. Breier A. Cognitive deficit in schizophrenia and its neurochemical basis. Br J Psychiatry Suppl. 1999(37):16-18.
34. Breese GR, Knapp DJ, Moy SS. Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev. 2002;26:441-455.
35. Sur C, Kinney GG. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs. 2004;13:515-521.
36. Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol. 2004;7:1-8.
37. Javitt DC. Glycine modulators in schizophrenia. Curr Opin Investig Drugs. 2002;3:1067-1072.
38. Marcus MM, Nomikos GG, Svensson TH. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur Neuropsychopharmacol. 1996;6:29-38.
39. Sakia K, Gao XM, Hashimoto T, Tamminga CA. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal-ganglia-thalmocortical neural pathways. Synapse. 2001;39:152-160.
40. Purdon SE, Woodward N, Lindborg SR, Stip E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl). 2003;169:390-397.
41. Deutsch JA, Hamburg MD, Dahl H. Anticholinesterase-induced amnesia and its temporal aspects. Science. 1966;151:221-223.
42. Deutsch JA. The cholinergic synapse and the site of memory. In: McGaugh J, ed. The Chemistry of Mood, Motivation, and Memory. New York, NY: Plenum Press; 1972:187-205.
43. Squire LR, Glick SD, Goldfarb J. Relearning at different times after training as affected by centrally and peripherally acting cholinergic drugs in the mouse. J Comp Physiol Psychol. 1971;74:41-45.
44. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116-124.
45. Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med. 2004;34:369-374.
46. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.
47. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002;26:325-339.
48. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
49. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34:702-712.
50. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238-246.
51. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159-1172.
52. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295:853-861.
53. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 1999;288:774-781.
54. Liegeois JF, Ichikawa J, Meltzer HY. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontral cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 2002;947:157-165.
55. Remington G. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neurosci. 2003;28:275-284.
56. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38.
57. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158:360-369.
58. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res. 2003;3:108-117.
59. Harvey PD. Paper presented at: American Psychiatric Association 55th Institute on Psychiatric Services; Octobet 30, 2003; Boston, Mass.
60. Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl). 2004;172:324-332.
61. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 (suppl 19):6-12.
62. Stahl SM. Psychopharmacology of Antipsychotics. London, England: Martin Dunitz Ltd.; 1999.
63. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197-201.
64. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
65. Harvey PD. Ziprasidone and cognition: the evolving story. J Clin Psychiatry. 2003;64(suppl 19):33-39.
66. Goff DC, Hennen J, Lyoo IK, et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002;51:493-497.
67. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55(Suppl B):82-87.
68. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59(Suppl 3):21-25.
69. Aguglia E, De Vanna M, Onor ML, Ferrara D. Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1229-1233.
70. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
71. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
72. Albus M, Hubmann W, Ehrenberg C, et al. Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1996;246:249-255.
73. Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol. 1998;125:1562-1566.
74. Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl) phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273-1276.
75. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994;268:1403-1410.
76. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol. 1997;7:701-707.